Down-regulation of liver drug-metabolizing enzymes in a murine model of chronic renal failure

Drug Metabolism and Disposition

Volumn 38, Issue 3, 2010, Pages 357-360

  Dani, Mélina ^a   Boisvert, Caroline ^a   Michaud, Josée ^a   Naud, Judith ^a   Lefrançois, Stéphane ^a   Leblond, Francois A ^a   Pichette, Vincent ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; CYTOCHROME P450 3A11; ERYTHROMYCIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DEMETHYLATION; DOWN REGULATION; DRUG METABOLISM; ENZYME ACTIVITY; GENE EXPRESSION; LIVER MICROSOME; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; CREATININE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ERYTHROMYCIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; ISOENZYMES; KIDNEY FAILURE, CHRONIC; LIVER; MALE; MICE; MICE, INBRED C57BL; NEPHRECTOMY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UREA;

ANIMALIA; MURINAE; MUS; RATTUS;

EID: 76749140012     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029991     Document Type: Article

References (29)

1. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, and Henrich WL (2003) Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73:427-434.
2. Dreisbach AW (2009) The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther 86:553-556.
3. Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJ, Kamath BL, and Rettie AE (2003) Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther 73:475-477.
4. Dreisbach AW and Lertora JJ (2003) The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 16:45-50.
5. Dreisbach AW and Lertora JJ (2008) The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 4:1065-1074.
6. du Souich P and Erill S (1978) Metabolism of procainamide in patients with chronic heart failure, chronic respiratory failure and chronic renal failure. Eur J Clin Pharmacol 14:21-27.
7. Gagnon RF and Ansari M (1990) Development and progression of uremic changes in the mouse with surgically induced renal failure. Nephron 54:70-76.
8. Gagnon RF and Duguid WP (1983) A reproducible model for chronic renal failure in the mouse. Urol Res 11:11-14.
9. Guévin C, Michaud J, Naud J, Leblond FA, and Pichette V (2002) Down-regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 137: 1039-1046.
10. Kim YG, Shin JG, Shin SG, Jang IJ, Kim S, Lee JS, Han JS, and Cha YN (1993) Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther 54:612-620.
11. Kren S and Hostetter TH (1999) The course of the remnant kidney model in mice. Kidney Int 56:333-337.
12. Leblond F, Guévin C, Demers C, Pellerin I, Gascon-Barré M, and Pichette V (2001) Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12:326-332.
13. Leblond FA, Giroux L, Villeneuve JP, and Pichette V (2000) Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 28:1317-1320.
14. Leblond FA, Petrucci M, Dubé P, Bernier G, Bonnardeaux A, and Pichette V (2002) Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 13:1579-1585.
15. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
16. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
17. Michaud J, Dubé P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, and Pichette V (2005) Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 144:1067-1077.
18. Mikula M, Dzwonek A, Hennig EE, and Ostrowski J (2005) Increased mitochondrial gene expression during L6 cell myogenesis is accelerated by insulin. Int J Biochem Cell Biol 37:1815-1828.
19. Nash T (1953) The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem J 55:416-421.
20. Nolin TD (2008) Altered nonrenal drug clearance in ESRD. Curr Opin Nephrol Hypertens 17:555-559.
21. Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, and Himmelfarb J (2006) Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 17:2363-2367.
22. Nolin TD, Naud J, Leblond FA, and Pichette V (2008) Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83:898-903.
23. Richardson TA and Morgan ET (2005) Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice. J Pharmacol Exp Ther 314:703-709.
24. Simard E, Naud J, Michaud J, Leblond FA, Bonnardeaux A, Guillemette C, Sim E, and Pichette V (2008) Downregulation of hepatic acetylation of drugs in chronic renal failure. J Am Soc Nephrol 19:1352-1359.
25. Stanley LA, Coroneos E, Cuff R, Hickman D, Ward A, and Sim E (1996) Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J Histochem Cytochem 44:1059-1067.
26. Sun H, Frassetto L, and Benet LZ (2006) Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109:1-11.
27. Tindberg N, Baldwin HA, Cross AJ, and Ingelman-Sundberg M (1996) Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury. Mol Pharmacol 50:1065-1072.
28. Wang RW, Newton DJ, Scheri TD, and Lu AY (1997) Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab Dispos 25:502-507.
29. Zimmermann C, van Waterschoot RA, Harmsen S, Maier A, Gutmann H, and Schinkel AH (2009) PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci 36:565-571.